AMPA受体拮抗剂在创伤性脑损伤临床前模型中的系统评价与荟萃分析
该系统评价与荟萃分析纳入11项哺乳动物在体TBI研究,评估伤后给予AMPA受体拮抗剂对比对照的效果。结果显示神经功能缺损评分(SMD 1.28,95%CI 0.05-2.50)与认知记忆(SMD 1.53,95%CI 1.06-2.01)改善,脑损伤严重度降低(SMD -1.39,95%CI -2.07至-0.71),炎症生物标志物一致降低,但运动协调与死亡率无显著影响。结论支持AMPA靶向神经保护的生物学合理性,但部分结果需谨慎解读,尚不足以改变临床实践。
要点
- 动物TBI模型中AMPA受体拮抗剂改善神经功能缺损评分:SMD 1.28(95%CI 0.05-2.50),异质性I2=78%,仅4项研究。
- 认知与记忆改善:SMD 1.53(95%CI 1.06-2.01),I2=3%,5项研究,异质性低。
- 脑损伤严重度降低:SMD -1.39(95%CI -2.07至-0.71),I2=53%,7项研究。
- 运动协调无显著改善:SMD -1.00(95%CI -2.96至0.96),I2=83%;死亡率无显著影响。
- 炎症生物标志物一致降低,但证据来自动物研究,不能直接外推至急诊/ICU患者。
适用人群与场景
- 纳入:哺乳动物在体TBI研究,AMPA受体拮抗剂在伤后给药,对照为溶媒、无治疗或替代干预。
- 排除:原文未提及具体排除标准。
- 场景:临床前动物模型,非急诊/ICU患者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:临床前动物研究的系统评价与荟萃分析,检索MEDLINE、Embase、Web of Science。
- 纳入11项研究(来自410条记录),采用CAMARADES清单与SYRCLE工具评估偏倚风险。
- 主要终点神经行为表现:神经功能缺损SMD 1.28(95%CI 0.05-2.50;I2=78%;4项研究),认知记忆SMD 1.53(95%CI 1.06-2.01;I2=3%;5项研究),运动协调SMD -1.00(95%CI -2.96至0.96;I2=83%;2项研究)。
- 次要终点:脑损伤严重度SMD -1.39(95%CI -2.07至-0.71;I2=53%;7项研究);死亡率无显著效应;炎症生物标志物一致降低。
证据类型、等级与局限
- 证据类型:临床前动物研究的系统评价与荟萃分析。
- 证据等级/推荐强度:原文未提及。
- 局限:仅纳入动物研究(11项),部分结局研究数少、异质性高(神经功能缺损I2=78%,运动协调I2=83%),原文指出部分结果需谨慎解读。
对床旁实践的改变
- 不改变当前急诊/ICU对TBI患者的临床实践:原文为动物研究证据,无人体推荐。
- 适用人群:仅限临床前哺乳动物TBI模型;不适用于急诊/ICU患者。
- 常见陷阱:不能将动物模型的SMD效应量误读为临床疗效阈值或治疗推荐。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: Traumatic brain injury (TBI) is a major cause of death and long-term disability, yet no pharmacological neuroprotective strategy has shown clear clinical benefit. Because excitotoxicity is a key mechanism of secondary brain injury, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists have emerged as promising candidates in preclinical research. We aimed to evaluate whether AMPA receptor antagonists improve neurobehavioural outcomes and reduce brain lesion severity, mortality and inflammatory biomarkers in in vivo animal models of TBI.
METHODS: We conducted a systematic review and meta-analysis of preclinical animal studies, searching MEDLINE, Embase and Web of science. We included mammalian in vivo TBI studies evaluating AMPA receptor antagonists administered after injury, compared with vehicle, no treatment, or an alternative intervention. Two reviewers independently screened studies, extracted data and assessed methodological quality and risk of bias using the Collaborative Approach to Meta-analysis and Review of Animal Data from Experimental Studies (CAMARADES) checklist and the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool. The primary outcome was neurobehavioural performance across three domains: neurological deficit, cognition and memory and motor coordination. Secondary outcomes included brain lesion severity, mortality and inflammatory biomarkers. Random-effects meta-analyses used standardized mean differences (SMDs).
RESULTS: Of 410 records, 11 studies were included. Compared with controls, AMPA receptor antagonists improved neurological deficit scores [SMD 1.28, 95% confidence intervals (CI) 0.05-2.50; I2 = 78%; four studies] and cognition and memory (SMD 1.53, 95% CI 1.06-2.01; I2 = 3%; five studies), but not motor coordination (SMD - 1.00, 95% CI - 2.96 to 0.96; I2 = 83%; two studies). Brain lesion severity was significantly reduced (SMD - 1.39, 95% CI - 2.07 to - 0.71; I2 = 53%; seven studies). Mortality showed no significant effect. Inflammatory biomarkers were consistently reduced with AMPA receptor antagonists.
CONCLUSIONS: In preclinical TBI models, AMPA receptor antagonists improved neurological and cognitive outcomes and reduced brain lesion severity, but not motor coordination or mortality, supporting the biological plausibility of AMPA-targeted neuroprotection, although some results should be interpreted with caution.
参考来源
- Gourier S, Morin C, Gargadennec T, et al. AMPA Receptor Antagonists in Preclinical Models of Traumatic Brain Injury: A Systematic Review and Meta-analysis of Animal Studies. Neurocrit Care. 2026. PMID: 42728509. doi:10.1007/s12028-026-02640-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。